OptiNose Inc (OPTN)
1.32
+0.03
(+2.33%)
USD |
NASDAQ |
May 20, 10:36
OptiNose Cash from Investing (TTM): -0.35M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -0.35M |
December 31, 2023 | -0.328M |
September 30, 2023 | -0.258M |
June 30, 2023 | -0.092M |
March 31, 2023 | -0.015M |
December 31, 2022 | -0.063M |
September 30, 2022 | -0.084M |
June 30, 2022 | -0.102M |
March 31, 2022 | -0.019M |
December 31, 2021 | -0.062M |
September 30, 2021 | -0.124M |
June 30, 2021 | -0.247M |
March 31, 2021 | -0.567M |
Date | Value |
---|---|
December 31, 2020 | -0.546M |
September 30, 2020 | -0.532M |
June 30, 2020 | -0.443M |
March 31, 2020 | -0.459M |
December 31, 2019 | -0.557M |
September 30, 2019 | -0.725M |
June 30, 2019 | -1.232M |
March 31, 2019 | -1.476M |
December 31, 2018 | -1.69M |
September 30, 2018 | -2.646M |
June 30, 2018 | -2.576M |
March 31, 2018 | -2.698M |
December 31, 2017 | -2.406M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-1.232M
Minimum
Jun 2019
-0.015M
Maximum
Mar 2023
-0.3402M
Average
-0.293M
Median
Cash from Investing (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | -217.60M |
Viking Therapeutics Inc | -641.08M |
Zevra Therapeutics Inc | 14.96M |
CytomX Therapeutics Inc | 40.85M |
Spero Therapeutics Inc | -- |